Heparin-Induced Thrombocytopenia Monitoring
Introduction to HIT Monitoring
- The American College of Chest Physicians recommends monitoring platelet counts every 2-3 days from day 4 to day 14 for surgical and trauma patients receiving unfractionated heparin (UFH), and every 2-4 days for medical and obstetric patients receiving UFH or postoperative low molecular weight heparin (LMWH) 1
- The American College of Chest Physicians recommends no routine platelet monitoring beyond baseline for medical patients receiving only LMWH 1
Special Considerations for HIT Monitoring
- For patients who received heparin within the previous 100 days, the American College of Chest Physicians recommends obtaining a baseline platelet count and a repeat count 24 hours after starting heparin 1
- For patients who develop acute inflammatory reactions or cardiorespiratory symptoms within 30 minutes of IV heparin bolus, the American College of Chest Physicians recommends performing an immediate platelet count 1
- If a patient received heparin within the previous 30-100 days, beginning platelet count monitoring on day 0 (day of initiation) and obtaining a repeat platelet count at 24 hours if feasible, is suggested 1
- If a patient received heparin within the previous 30 days, begin platelet count monitoring on day 0 (day of heparin initiation), according to the American College of Cardiology 2
Key Indicators for HIT Evaluation
- A platelet count drop of ≥50% from baseline should prompt immediate HIT evaluation, as recommended by the American College of Chest Physicians 1
- New thrombotic events while on heparin should prompt immediate HIT evaluation, as recommended by the American College of Chest Physicians 1
- Skin necrosis or unusual reactions after heparin injection should prompt immediate HIT evaluation, as recommended by the American College of Chest Physicians 1
The American Society of Hematology and the American College of Chest Physicians recommend platelet count monitoring for HIT, stratified by patient risk category:
Patient Risk Category Monitoring Schedule Low-risk no routine monitoring Intermediate-risk twice weekly monitoring from days 4-14 High-risk every-other-day monitoring from days 4-14
Monitoring Schedules
Medical, obstetric, surgical, and trauma patients receiving heparin should have their platelet counts monitored according to the following schedules:
Patient Type Monitoring Schedule Medical and obstetric once to twice weekly from day 4 to day 14, then weekly for one month if heparin therapy continues Surgical and trauma every other day (2-3 times weekly) from day 4 to day 14, then weekly for one month if heparin therapy continues Monitoring of hemoglobin, hematocrit, and platelet count should be performed every 2-3 days up to at least day 14, then every 2 weeks thereafter, as recommended by the National Comprehensive Cancer Network (NCCN) 4
Baseline Laboratory Tests and Contraindications
- Baseline laboratory tests should include complete blood count (CBC) with platelet count, activated partial thromboplastin time (aPTT), prothrombin time (PT)/International Normalized Ratio (INR) if patient is on or will transition to warfarin, and serum creatinine and creatinine clearance, especially if renal dysfunction is suspected 2
- Contraindications to subcutaneous heparin therapy include active major bleeding, severe thrombocytopenia, recent spinal anesthesia/lumbar puncture, and intracranial or spinal lesions at high risk for bleeding, according to the National Comprehensive Cancer Network (NCCN) 4
Management of Suspected HIT
- If HIT is suspected, immediately discontinue all heparin products, calculate the 4T score to determine clinical probability of HIT, order appropriate laboratory testing, and initiate alternative anticoagulation with a direct thrombin inhibitor or factor Xa inhibitor, as recommended by the American Society of Hematology 3
- Avoid vitamin K antagonists until platelet count has substantially recovered, and perform lower extremity ultrasound to evaluate for occult deep vein thrombosis, according to the American College of Cardiology 3
- The strength of evidence for these recommendations is based on expert opinion and clinical experience, with a moderate to high level of evidence supporting the importance of baseline laboratory testing and monitoring for HIT risk 2